Analysis shows improved accuracy in diagnosing oncocytic thyroid nodules, suggesting better management options.
Afirma GSC has a high BCR and improved performance over earlier generation molecular tests in oncocytic thyroid nodules, particularly for Bethesda IV. However, the PPV in Bethesda III nodules remains low, especially in the presence of Hashimoto's thyroiditis.
No takes yet. Share an insight, caveat, or question.
Ahmadi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: